



California Association of Health Facilities
2201 K Street, Sacramento, California 95816

CARE CONSIDERATIONS-RESIDENT WITH BEHAVIOR AND PSYCHOTIC SYMPTOMS OF DEMENTIA

TABLE OF CONTENTS

USE OF THIS RESOURCE.....	2
CARE OF RESIDENT WITH BEHAVIOR/PSYCHOTIC SYMPTOMS OF DEMENTIA.....	3
POLICY ELEMENTS.....	3
Recognition/Assessment	3
Cause Identification/Diagnosis	3
Care Planning	4
Monitoring/Follow-up	6
Quality Assurance Performance Improvement.....	7
Resources	7
APPENDIX A	8
INFORMED CONSENT TOOL KIT.....	8
Requirement	8
Physician/Health Care Practitioner Responsibility	8
Facility Role	8
Verification of Informed Consent	8
Facility Obligation to Fully Inform Resident/RP of Health Status.....	9
Exceptions To Obtaining Informed Consent.....	9
Resident Lacks Capacity and No Legally Authorized Decision Maker	10
EXHIBITS	
Verification of Informed Consent (Antipsychotic).....	11
Resident/Responsible Party Verification of Informed Consent.....	12
Verification of Informed Consent (Psychoactive).....	13
Resident/Responsible Party Verification of Informed Consent.....	14
Sample FDA Antipsychotic Side Effects Information	15
Sample Antipsychotic Side Effects Information Pamphlet	17

Draft Not For Distribution

USE OF THIS RESOURCE

This evidence-based structure and process guidance is provided as a resource to facilities who are serving residents with challenging behaviors and psychotic symptoms related to dementia. The information in this document is intended as a reference tool only to assist senior leadership to evaluate their resident assessment, care planning, informed consent and facility quality assessment and assurance practices related to non-pharmacological and pharmacological interventions. We recommend that it be used as “quality assurance/performance improvement tool” and hope that it will assist care providers to support those residents who are exhibiting dementia-related behaviors and psychotic symptoms to maintain their highest practicable level of well-being.

DISCLAIMER

THIS CARE CONSIDERATIONS-RESIDENT WITH BEHAVIOR AND PSYCHOTIC SYMPTOMS OF DEMENTIA DOCUMENT FROM THE CALIFORNIA ASSOCIATION OF HEALTH FACILITIES (CAHF) IS EXCLUSIVELY INTENDED TO PROVIDE GUIDANCE. IT DOES NOT CONTAIN OR CONSTITUTE LEGAL ADVICE IN ANY FORM AND DOES NOT MAKE ANY ASSURANCE OR REPRESENTATION THAT THE GUIDANCE CONTAINED HEREIN WILL BE DETERMINED TO CONSTITUTE COMPLIANCE WITH ANY STATE OR FEDERAL LAW OR REGULATION. IN ADDITION, CAHF IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS CONTAINED IN THE CARE CONSIDERATIONS-RESIDENT WITH BEHAVIOR AND PSYCHOTIC SYMPTOMS OF DEMENTIA DOCUMENT AND ASSUME NO RESPONSIBILITY FOR THE MISUSE OR ERRONEOUS INTERPRETATION OF ITS CONTENTS.

CARE CONSIDERATIONS-RESIDENT WITH BEHAVIOR AND PSYCHOTIC SYMPTOMS OF DEMENTIA

POLICY ELEMENTS	
I. FOUNDATIONAL STRATEGIES	
<ul style="list-style-type: none"> • Require administrative review of all newly prescribed psychotropic medications • Consistent assignments • Individualize routines (ADL, meals, activities, sleep/wake) • Adequate staffing (nursing, activities, social services) • Resident/family involvement in plan of care 	
II. RECOGNITION/ASSESSMENT	
Reference: CFR § 483.20 F Tag 272, CCR Title 22 72311 (a) (1) (A)	
REQUIREMENT: The facility must conduct initially and periodically a comprehensive accurate assessment of residents functional capacity and identify their care needs	
a. ASSESSMENT	
Identify frequency, pattern of occurrence, impact, what makes the behavior better or worse and, if possible, the precipitating factors and consequences of the behavior.	
Utilize:	
<ul style="list-style-type: none"> • comprehensive assessment information • systematic review of medical record • Input from facility consultants (e.g. pharmacists, psychiatrist/psychologist) • interviews resident, care givers, and families • Observation 	
Describe:	
<ul style="list-style-type: none"> • Onset • Duration • Intensity 	
Document findings including discussion of whether or not the behaviors present a danger (including significant impact on functional ability) to self or others	
b. CAUSE IDENTIFICATION/DIAGNOSIS	
Identify triggers for the behavior and psychotic symptoms of dementia (BPSD)	
Unmet physical needs: Interdisciplinary Team (IDT) to evaluate, identify (ID) root causes through evaluation or changes to physical care	
Rule out: <ul style="list-style-type: none"> • Infection/illness • Electrolyte imbalance • Pain • Hunger • Thirst • Urinary distress • Constipation • Sensory Deficits • Fatigue 	Consider: <ul style="list-style-type: none"> • Medical evaluation • Labs • Empirical trial of analgesics • Snacks/meal adjustments • Increased fluids • Medical evaluation • Toileting program • Bowel care

<ul style="list-style-type: none"> • Sleep disturbance • Medication side effects 	<ul style="list-style-type: none"> • Hearing/vision aids • Lighting • Sleep evaluation/sleep hygiene program • Adequate rest/exercise, mobility/strengthening • Medication review
<p>Unmet environmental needs: IDT to evaluate, ID root causes through adaptation or change to environment</p>	
<p>Rule out:</p> <ul style="list-style-type: none"> • Noise level • Crowded area • Poor lighting • Restraints • Caregiver approach • Institution routine • Lack of cues for way find 	<p>Consider:</p> <ul style="list-style-type: none"> • Eliminate things that agitate or confuse • Adjust stimulation • Add functional cues (signs, pictures, lighting) • Change the setting (homelike, outdoors, spa bath setting) • Change approach (simple words, friendly tone, try later, redirect, don't confront)
<p>Unmet psychological needs: IDT to evaluate, ID root cause(s) and consider appropriate individualized interventions:</p>	
<p>Rule out:</p> <p>Unmet psychological needs</p> <ul style="list-style-type: none"> • Loneliness • Boredom • Fear/worry • Frustration • Confusion • Grief • Lack of enjoyable activity • Lack of socialization • Sudden situational change (e.g. loss of a spouse) 	<p>Consider interventions geared to:</p> <ul style="list-style-type: none"> • Resident's cognitive level, • Physical functional level, • long standing personality, life history, interests • Preferred personal routines

Psychiatric Causes: IDT to consult with medical director and/or attending physician to determine need for follow up	
Rule out: <ul style="list-style-type: none"> • Depression • Anxiety • Delirium • Psychosis • Other mental illness 	Consider: <ul style="list-style-type: none"> • Utilize all data sources to paint a comprehensive clinical picture for MD • Use the SBAR format to summarize info for report to MD • Include information on what interventions have been tried and the effect • Follow up as indicated
III. CARE PLANNING Reference: CFR § 483.10 (d) (3) F Tag 280, CCR Title 22 72527(a)(3)	
REQUIREMENT: A facility must use the results of the assessment to develop the resident’s comprehensive plan of care; must correctly and adequately describe the purpose and goals of the care and individualize interventions; and must support the resident or their responsible person’s right to participate in the planning of care and treatment.	
Based on assessment, develop a person-centered plan of care that is measurable and time limited; identifies desired outcomes; includes systems to monitor and evaluate effectiveness of care	
a. NON PHARMACOLOGICAL INTERVENTIONS	
Address physical needs through evidenced based approaches to:	
<ul style="list-style-type: none"> • Manage pain 	
<ul style="list-style-type: none"> • Support rest 	
<ul style="list-style-type: none"> • Maximize nutrition 	
<ul style="list-style-type: none"> • Eliminate illness/metabolic imbalance 	
<ul style="list-style-type: none"> • Provide exercise to support optimal physical function 	
<ul style="list-style-type: none"> • Address sensory deficits 	
<ul style="list-style-type: none"> • Mitigate medication side effects 	
Address psychological needs through individualized approaches based on person’s life history, routines and preferences, cognitive and physical functioning level	
<ul style="list-style-type: none"> • Engage in meaningful activity (tactile, manipulative, physical) 	
<ul style="list-style-type: none"> • Provide pleasurable experiences including individualized music and comfort foods, massage, aroma therapy 	
<ul style="list-style-type: none"> • Simplify daily routine to reflect individual’s rhythms 	
<ul style="list-style-type: none"> • Facilitate contact with favorite others (family, children, friends, caregivers, pets) 	
<ul style="list-style-type: none"> • Provide cues for way finding (pictures, signs, verbal cues) 	
<ul style="list-style-type: none"> • Adjust caregiver approach (focus on person not task, redirect, try later, reassure, comfort, accept, don’t challenge) 	
<ul style="list-style-type: none"> • Communicate effectively (simple words and phrases, wait for answers, make eye contact, wait for response, calm tone) 	

Address environmental needs through adapting and/or changing the environment, not the person
<ul style="list-style-type: none"> • Eliminate misleading stimuli (clutter, TV, noise, people)
<ul style="list-style-type: none"> • Reduce environmental stress (alarms, restraints, caffeine, decorations)
<ul style="list-style-type: none"> • Adjust the level of stimulation (more if bored, less if agitated)
<ul style="list-style-type: none"> • Adapt the physical environment to reflect individualized needs (homelike, lighting, smaller areas, low noise, natural light, outdoor time)
Address psychiatric needs through medical evaluation, psychiatric consult
<ul style="list-style-type: none"> • Employ nonpharmacological approaches as appropriate to do so
<ul style="list-style-type: none"> • Follow doctor's orders and/or consultant recommendations for additional pharmacological/behavioral interventions
<ul style="list-style-type: none"> • Comply with requirements for informed consent (SEE APPENDIX A – Informed Consent Tool Kit)
IV. MONITORING/FOLLOW UP
Reference: CFR § 482.20(d) F Tag 279, CFR § 483.25(l) F Tag 329, CFR § 483.60(c) F Tag 428, CFR §483.75(i) F Tag 501
REQUIREMENT: The facility must monitor the effectiveness of the interventions in helping the resident progress toward defined goals; adjust interventions as needed; identify the presence of adverse consequences from interventions; and identify when care objectives have been sufficiently achieved.
a. MONITOR
Care plans are monitored and plans are adjusted as indicated
<ul style="list-style-type: none"> • The IDT implements interventions consistently
<ul style="list-style-type: none"> • Target behaviors are identified in the resident plan of care and monitored objectively and quantitatively consistent with the primary indication for use as identified by the physician and IDT.
<ul style="list-style-type: none"> • In collaboration with the medical director or attending physician, consultant practitioners, and resident the IDT reviews and determine effectiveness of interventions
<ul style="list-style-type: none"> • If pharmacological interventions are used, appropriate side effects monitoring is in place and the team is aware of and has process for identifying any potential medication side effects.
<ul style="list-style-type: none"> • Behavioral data are made available to the prescriber in a consolidated manner at least monthly and information is sufficient to determine medication effectiveness as well and presence of any adverse consequences.
<ul style="list-style-type: none"> • Gradual dose reduction is attempted at least quarterly during two separate quarters initially, and then annually unless contraindicated.
<ul style="list-style-type: none"> • The pharmacist reviews the resident record monthly.
<ul style="list-style-type: none"> • If drug irregularities are identified, the information is provided in writing to the attending physician and director of nursing.
<ul style="list-style-type: none"> • The facility has a process for acting upon any pharmacist-identified drug irregularities.
<ul style="list-style-type: none"> • The facility utilizes the QAA process to evaluate issues related to informed consent for antipsychotic/psychotherapeutic medication use.

b. REVISE & UPDATE
<ul style="list-style-type: none"> In collaboration with the medical director/ attending physician, consultant practitioners, and resident the IDT reviews and determine effectiveness of interventions
<ul style="list-style-type: none"> If resident's behaviors do not improve or worsen, evaluate the root cause(s) <ul style="list-style-type: none"> Interventions not implemented consistently? Staff needs more training and/or accountability? Wrong interventions? Inadequate time to evaluate effectiveness?
<ul style="list-style-type: none"> Involve family and/or resident
<ul style="list-style-type: none"> Adjust approach, change or continue interventions as indicated
<ul style="list-style-type: none"> Care plan revised and updated as indicated
V. QUALITY ASSURANCE PERFORMANCE IMPROVEMENT
Reference: CFR§ 483.75(o) F Tag 520
The facility identifies quality concerns related to care of residents with dementia
QAA Committee monitors and provides oversight for dementia care related areas including:
<ul style="list-style-type: none"> Resident Care Policies and Procedures reflect the facility's overall approach to care of residents with dementia
<ul style="list-style-type: none"> Staff follow policies and procedures in developing and applying the interventions for the care of residents with dementia
<ul style="list-style-type: none"> CNAs receive initial and annual dementia care
<ul style="list-style-type: none"> There are sufficient staff to carry out interventions
<ul style="list-style-type: none"> Staff collect and analyze data to monitor the non-pharmacological (individualized, person-centered) interventions used to care for residents with dementia
<ul style="list-style-type: none"> Committee helps the facility to monitor trends, identify successes, and target areas for future improvement in the non-pharmacological management of behavior and psychotic symptoms in residents with dementia
VI. Resources
Federal Code of Regulations State Operations Manual Appendix PP https://www.cms.gov/Center/Provider-Type/Skilled-Nursing-Facility-Center.html?redirect=/center/snf.asp
California Code of Regulations Title 22 http://ccr.oal.ca.gov/linkedslice/default.asp?SP=CCR-1000&Action=Welcome
California Health and Safety Code http://www.leginfo.ca.gov/calaw.html
Improving Antipsychotic Appropriateness in Dementia Patients (IA-ADAPT) Website https://www.healthcare.uiowa.edu/igec/iaadapt/
Advancing Excellence CMS Partnership To Improve Dementia Care http://www.nhqualitycampaign.org/star_index.aspx?controls=dementiaCare
National Institute of Mental Health, Health Topics, Mental Health Medications www.nih.gov

APPENDIX A Informed Consent Tool Kit

<p>INFORMED CONSENT VERIFICATION FOR ANTIPSYCHOTIC/PSYCHOTHERAPEUTIC MEDICATIONS</p> <p>Reference: Title 22, CCR, Section 72527 and 72528, Health and Safety Code (HSC Sections 1418.8 and 1418.9)</p>
<p>The facility shall verify that the physician has obtained informed consent as follows:</p>
<ul style="list-style-type: none"> • Prior to initiation of antipsychotic or other psychotherapeutic medication;
<ul style="list-style-type: none"> • Prior to increase in dosage of an antipsychotic medication.
<p>A. PHYSICIAN/ HEALTHCARE PRACTITIONER RESPONSIBILITY</p> <p>Reference: HSC 1418.9, Title 22, CCR, Section 72528, CFR §483.75(i) F Tag 501</p> <p>The physician is the sole healthcare practitioner who is authorized to obtain informed consent for antipsychotic medications. Informed consent must include material information as specified in state regulation.</p> <p>NOTE: Other healthcare practitioners, within the scope of their licensure, may obtain informed consent for all other types of psychotherapeutic medications.</p>
<p>The physician will discuss with the resident/ responsible party (RP) information that is material to obtaining informed consent. (See CAHF Exhibits 1A and 1B for examples of the type of written information that the physician <u>may</u> provide.)</p>
<p>Within 48 hours of initiating or increasing the dose of an antipsychotic medication, when the <u>resident consents to notify an interested family member</u> the physician or designee shall make reasonable attempts to make such notification.</p>
<p>B. FACILITY ROLE IN INFORMED CONSENT</p> <p>Reference: HSC 1418.9, Title 22, CCR, Section 72528, CFR §483.75(i) F Tag 501</p>
<p>As specified in state regulation and statute, the facility's role in the informed consent process is limited to verifying that the physician obtained informed consent. The physician and/or licensed healthcare practitioner (as appropriate) within the scope of his/her licensure is deemed to have the technical knowledge to assure adequate disclosure of information, including that pertaining to the risks of treatment, has been given to the resident or RP.</p>
<ul style="list-style-type: none"> • The facility has written patients' rights policies and procedures related to antipsychotic/psychotherapeutic medication informed consent that include: • How the facility will verify that informed consent was obtained or refused that identifies all ways in which verification may occur and be documented in the resident record. • How the facility, in consultation with the resident's physician will identify who may serve as a resident's representative when an incapacitated patient has no conservator or attorney in fact under a valid Durable Power of Attorney for Health Care. • The medical director has ensured that resident care policies and procedures were implemented.
<ul style="list-style-type: none"> • Implemented regarding antipsychotic informed consent.
<p>C. DOCUMENTING VERIFICATION OF INFORMED CONSENT</p> <p>Reference: Title 22, CCR, Section 72527 and 72528, CFR §483.75(i) F Tag 501</p>
<p>The resident record must reflect that informed consent has been obtained by the healthcare practitioner</p> <p>NOTE: Only a physician may obtain informed consent for antipsychotic medication from the resident/RP. Documentation may include one or more of the following:</p>
<ul style="list-style-type: none"> • A copy of the informed consent obtained by the healthcare practitioner ordering the medication prior to admission to facility.
<ul style="list-style-type: none"> • The healthcare practitioner's signature and/or notes in the resident record verifying that

informed consent has been obtained from the resident/RP.
<ul style="list-style-type: none"> The signature of the licensed nurse verifying receipt of a verbal and/or written confirmation from the healthcare practitioner that informed consent has been obtained.
<ul style="list-style-type: none"> A signed copy of "Verification of Informed Consent for Antipsychotic Medication (see CAHF sample form 1-1)
OR
<ul style="list-style-type: none"> For psychotherapeutic medication: a signed copy of "Verification of Informed Consent for Psychotherapeutic Medication (see CAHF sample form 1-2).
<ul style="list-style-type: none"> A signed copy of "Resident/RP Consent for Use of Antipsychotic Medication (see CAHF sample form 2-1)
OR
<ul style="list-style-type: none"> A signed copy of "Resident/RP Consent for Use of Psychotherapeutic Medication (see CAHF sample form 2-2)
D. FACILITY OBLIGATION TO FULLY INFORM RESIDENT/RP OF HEALTH STATUS Reference: CFR § 483.10(b)(2) and (3) F Tags 153 and 154
The facility is responsible for assuring: <ul style="list-style-type: none"> Each resident is fully informed of his or her total health status, including but not limited to his/her medical condition. The resident is fully informed in advance about care and treatment and of any changes in that care or treatment that may affect the resident's well-being. At any time, should the resident/RP indicate doubt or confusion about the use of antipsychotic/psychotherapeutic medication, or withdraw consent for same, contact the physician and/or the licensed health care practitioner (as appropriate).
E. EXCEPTIONS TO OBTAINING INFORMED CONSENT Reference: Title 22, CCR, Section 72528
There is documentation within the resident record that any of the following conditions are present:
<ul style="list-style-type: none"> An emergency exists where there is an unanticipated condition in which immediate action is necessary for the preservation of life or the prevention of serious bodily harm, to the resident or others or to alleviate severe physical pain, and it is impractical to obtain the required consent and that the action taken is within the customary practice of the licensed healthcare practitioners of good standing acting within the scope of their professional licensure in similar circumstances.
<ul style="list-style-type: none"> The resident or RP specifically requested that he/she is not to be informed of the risks of the recommended treatment

- That the licensed healthcare practitioner acting within his/her scope of professional licensure, relied upon objective facts, as documented in the health record, that would demonstrate to a reasonable person that the disclosure would have so seriously upset the resident that the resident would not have been able to rationally weight the risks of refusing to undergo the recommended treatment and that, unless inappropriate, a resident's representative gave informed consent as set forth herein.

F. RESIDENT LACKS CAPACITY AND NO LEGALLY AUTHORIZED DECISION MAKER

Reference: HSC Section, 1418.8

Requirement:

If the attending physician determines the resident lacks capacity and there is no person with legal authority to make those decisions on behalf of the resident, the MD shall inform the facility.

- The resident record contains documentation that there is no person who has legal authority who can or will make health care decisions as determined by the attending physician.
- IDT will review the proposed prescribed medical intervention prior to the administration of the proposed medication.
- The IDT shall include a registered nurse who has responsibility for the resident, other appropriate staff in disciplines as determined by the resident's needs and, where practicable, a patient representative.

The IDT review shall include the following:

- A review of the physician's assessment of the resident's condition.
- The reason for the proposed use of the medical intervention.
- The type of medical intervention to be used in the resident's care including its probable frequency and duration.
- The probable impact on the resident's condition, with and without the use of the medical intervention.
- Reasonable alternative medical interventions considered or utilized and reasons for their discontinuance or inappropriateness.

The IDT shall periodically evaluate the use of the prescribed medical intervention at least quarterly or upon a significant change in the resident's medical condition.

- **EXCEPTION:** In the case of an emergency, a medical intervention may be administered which requires informed consent prior to convening an IDT review. The IDT shall meet within one week of the emergency for evaluation of the medical intervention.

Verification of Informed Consent for Antipsychotic Medication

Resident name: _____

Medication : _____	Expected Dosage Range: _____
Specific medical condition / psychiatric diagnosis:	
<input type="checkbox"/> Schizophrenia	
<input type="checkbox"/> Schizoaffective Disorder	
<input type="checkbox"/> Delusional Disorder	
<input type="checkbox"/> Mood Disorders (e.g., Bipolar Disorder, Depression with Psychotic Features, Refractory Depression)	
<input type="checkbox"/> Schizophreniform Disorders	
<input type="checkbox"/> Psychosis	
<input type="checkbox"/> Brief Psychotic Disorder	
<input type="checkbox"/> Dementing illnesses w/ associated behavioral symptoms	
<input type="checkbox"/> Medical illnesses w/psychotic symptoms and/or related to psychosis/ mania/delirium	
<input type="checkbox"/> Tourette's or Huntington's	
<input type="checkbox"/> Hiccups or Nausea and Vomiting associated with cancer or chemotherapy	
<input type="checkbox"/> Other: _____	
Potential/Expected Benefits:	
Side Effects / Severity of Risks:	
<input type="checkbox"/> Physician requests the facility send attached information about the medication and a copy of this form to resident and/or resident's surrogate decision-maker. Date sent _____ Signature _____	
Warning for Antipsychotic Medication	
<i>The Food and Drug Administration (FDA) issued a Public Health Advisory for atypical antipsychotic medications. The FDA determined that the death rates are higher for elderly people with dementia when taking this medication. A review of the data has found a risk with conventional antipsychotics as well. Antipsychotic medications are not FDA approved for the treatment of behavioral disorders in patients with dementia. Source: National Institute of Mental Health U.S. Department of Health and Human Services www.nih.gov</i>	

INFORMED CONSENT VERIFICATION (CHECK BOX THAT APPLIES)

I have discussed with _____, the following:

Circle one: resident and/or the resident's surrogate decision-maker

- The reason for the treatment and the nature and seriousness of the resident's illness
- The nature of the proposed treatment including frequency and duration
- The probable degree and duration (temporary or permanent) of improvement or remission, expected with or without such treatment
- The nature, degree, duration, and probability of the side effects and significant risks (e.g., FDA boxed warning), commonly known by the health professions
- The reasonable alternative treatments and risks, and why the health professional is recommending this particular treatment
- That the resident has the right to accept or refuse the proposed treatment, and if he or she consents, has the right to revoke his or her consent for any reason at any time.

The above-named resident and/or the resident's surrogate decision-maker has given permission for use of the medication.

The above-named resident has given permission to contact a designated family member regarding the use of anti-psychotic medication.

The above-named resident has **not given permission** to contact a designated family member regarding the use of anti-psychotic medication.

Ordering Physician's Signature Date

Licensed Nurse Signature Verifying Evidence of Informed Consent Date

Resident/Surrogate Decision Maker Informed Consent for Antipsychotic Medication

Resident name: _____

Medication : _____	Expected Dosage Range: _____
Specific medical condition / psychiatric diagnosis:	
<input type="checkbox"/> Schizophrenia	
<input type="checkbox"/> Schizoaffective Disorder	
<input type="checkbox"/> Delusional Disorder	
<input type="checkbox"/> Mood Disorders (e.g., Bipolar Disorder, Depression with Psychotic Features, Refractory Depression)	
<input type="checkbox"/> Schizophreniform Disorders	
<input type="checkbox"/> Psychosis	
<input type="checkbox"/> Brief Psychotic Disorder	
<input type="checkbox"/> Dementing illnesses w/ associated behavioral symptoms	
<input type="checkbox"/> Medical illnesses w/psychotic symptoms and/or related to psychosis/ mania/delirium	
<input type="checkbox"/> Tourette's or Huntington's	
<input type="checkbox"/> Hiccups or Nausea and Vomiting associated with cancer or chemotherapy	
<input type="checkbox"/> Other: _____	
Potential/Expected Benefits:	
Side Effects / Severity of Risks:	
<input type="checkbox"/> See attached information sheet for additional information about this medication	
Warning for Antipsychotic Medication	
<i>The Food and Drug Administration (FDA) issued a Public Health Advisory for atypical antipsychotic medications. The FDA determined that the death rates are higher for elderly people with dementia when taking this medication. A review of the data has found a risk with conventional antipsychotics as well. Antipsychotic medications are not FDA approved for the treatment of behavioral disorders in patients with dementia. Source: National Institute of Mental Health U.S. Department of Health and Human Services www.nih.gov</i>	

INFORMED CONSENT VERIFICATION (CHECK BOX THAT APPLIES)

The physician has discussed the following:

- The reason for the treatment and the nature and seriousness of the resident's illness
- The nature of the proposed treatment including frequency and duration
- The probable degree and duration (temporary or permanent) of improvement or remission, expected with or without such treatment
- The nature, degree, duration, and probability of the side effects and significant risks (e.g., FDA boxed warning), commonly known by the health professions
- The reasonable alternative treatments and risks, and why the health professional is recommending this particular treatment
- That the resident has the right to accept or refuse the proposed treatment, and if he or she consents, has the right to revoke his or her consent for any reason at any time.

I have given permission for use of the medication.

Resident Signature

Date

or

Resident's Surrogate Decision-maker

Date

Verification of Informed Consent for Psychoactive Medication

Resident name: _____

Medication : _____	Expected Dosage Range: _____
Symptoms to be treated:	
Potential/Expected Benefits:	
Side Effects / Severity of Risks:	
<input type="checkbox"/> Physician requests the facility send attached information about the medication and a copy of this form to resident and/or resident's surrogate decision-maker. Date sent _____ Signature _____	

INFORMED CONSENT VERIFICATION (CHECK BOX THAT APPLIES)

I have discussed with _____, the following:

Circle one: resident and/or the resident's surrogate decision-maker

- The reason for the treatment and the nature and seriousness of the resident's illness
- The nature of the proposed treatment including frequency and duration
- The probable degree and duration (temporary or permanent) of improvement or remission, expected with or without such treatment
- The nature, degree, duration, and probability of the side effects and significant risks (e.g., FDA boxed warning), commonly known by the health professions
- The reasonable alternative treatments and risks, and why the health professional is recommending this particular treatment
- That the resident has the right to accept or refuse the proposed treatment, and if he or she consents, has the right to revoke his or her consent for any reason at any time.

The above-named resident and/or the resident's surrogate decision-maker has given permission for use of the medication.

Ordering Physician's Signature

Date

Licensed Nurse Signature Verifying Evidence of Informed Consent

13

Date

Resident/Surrogate Decision Maker Informed Consent for Psychoactive Medication

Resident name: _____

Medication : _____	Expected Dosage Range: _____
Symptoms to be treated:	
Potential/Expected Benefits:	
Side Effects / Severity of Risks:	
<input type="checkbox"/> See attached information sheet for additional information about this medication	

INFORMED CONSENT VERIFICATION (CHECK BOX THAT APPLIES)

The physician has discussed the following:

- The reason for the treatment and the nature and seriousness of the resident's illness
- The nature of the proposed treatment including frequency and duration
- The probable degree and duration (temporary or permanent) of improvement or remission, expected with or without such treatment
- The nature, degree, duration, and probability of the side effects and significant risks (e.g., FDA boxed warning), commonly known by the health professions
- The reasonable alternative treatments and risks, and why the health professional is recommending this particular treatment
- That the resident has the right to accept or refuse the proposed treatment, and if he or she consents, has the right to revoke his or her consent for any reason at any time.

I have given permission for use of the medication.

Resident Signature

Date

or

Resident's Surrogate Decision-maker

Date



Patient Information Sheet

Clozapine (marketed as Clozaril)

This is a summary of the most important information about Clozaril. For details, talk to your healthcare professional.

What is Clozaril?

Clozaril is a prescription medicine used to treat people with severe forms of schizophrenia that have not responded to or cannot take other treatments. Clozaril is also used to lower the risk of suicidal behavior in people with schizophrenia or schizoaffective disorder. Clozaril is not approved for use in children.

Who Should Not Take Clozaril?

You should not take Clozaril if:

- You are taking other medicines that can cause the same serious bone marrow side effects as Clozaril.
- You can ask your healthcare professional for a complete list of these medications.

What are The Risks?

The following are the risks and potential side effects of Clozaril therapy. However, this list is not complete.

- **Increased chance of death in elderly persons.** Elderly patients treated with atypical antipsychotics, such as Clozaril, for dementia had a higher chance for death than patients who did not take the medicine. Clozaril is not approved for dementia.
- **Agranulocytosis**, a potentially life-threatening reaction where the body's bone marrow does not produce enough white blood cells. Because of this risk, your healthcare professional must monitor your blood while you are taking Clozaril.
- **Seizures.** The risk of seizure is increased in people who have a history of seizures or other predisposing factors. Because of this risk you should not engage in any activity where you may suddenly lose consciousness, such as operating complex machinery, driving, swimming, climbing, etc.
- **Heart problems.** Clozaril can cause a condition called myocarditis, or swelling of the heart muscle. Some of the warning signs of myocarditis are tiredness, shortness of breath, rapid breathing, fever, chest pain, and irregular

heart beat. If these happen, call your healthcare professional right away.

- **Lowering of blood pressure** when you stand up. This may also lead to fainting. In rare instances, this has been associated with lung and/or heart collapse.

Clozaril and other antipsychotic medications can cause serious problems such as:

- **A life-threatening nervous system problem called neuroleptic malignant syndrome (NMS).** NMS can cause a high fever, stiff muscles, sweating, a fast or irregular heart beat, change in blood pressure, and confusion. NMS can affect your kidneys. NMS is a medical emergency. Call your healthcare professional right away if you experience these symptoms.
- **A movement problem called tardive dyskinesia (TD).** Call your healthcare professional right away if you get muscle movements that cannot be stopped.
- **High blood sugar and diabetes.** Patients with diabetes or who have a higher chance for diabetes should have their blood sugar checked often.
- **Other serious side effects may** include fever, blood clots in the lung, increased blood sugar, and liver disease.
- **The most common side effects** include drowsiness, increased salivation, rapid heart beat, dizziness, constipation, headache, shaking, and lightheadedness.

What Should I Tell My Healthcare Professional?

Before you start using Clozaril, tell your healthcare professional if you:

- have or had heart or lung problems
- have or had seizures
- have or had blood clots
- have or had diabetes or increased blood sugar
- have or had liver disease
- have or had glaucoma
- have or had stomach problems
- have or had prostate enlargement
- are trying to become pregnant, are already pregnant, or are breast-feeding
- drink alcohol
- smoke



Questions? Call Drug Information, 1-888-INFO-FDA (automated) or 301-827-4570

Druginfo@fda.hhs.gov



Patient Information Sheet

Clozapine (marketed as Clozaril)

Are There Any Interactions With Drugs or Foods?

Because certain other medications can interact with Clozaril, review all medications that you are taking with your health care professional, including those that you take without a prescription. You should not take Clozaril if you are taking other medicines that can cause the same serious bone marrow side effects as Clozaril.

Your healthcare professional may have to adjust your dose or watch you more closely if you take the following medications:

- certain medicines used to treat anxiety, called benzodiazepines
- certain medicines used to clear thoughts, called psychotropic drugs
- epinephrine
- phenytoin
- rifampin
- cimetidine

- erythromycin
- carbamazepine
- fluvoxamine
- paroxetine

Avoid drinking alcohol while taking Clozaril.

Is There Anything Else I Need to Know?

- Dizziness, and sometimes fainting, caused by a drop in blood pressure may happen with Clozaril, especially when you first start taking this medicine or when the dose is increased.
- Clozaril may impair judgment, thinking, or motor skills. You should be careful in operating machinery, including automobiles, until you know how Clozaril affects you.

**Clozaril FDA Approved 1989
Patient Information Sheet Revised 09/2006**



You Have The Right To be Fully Informed About The Benefits and Risks of Antipsychotic Medication

Your Company Logo will Appear Here

California Informed Consent Requirements

California Code of Regulations, Title 22 § 72528

(a) It is the responsibility of the attending licensed healthcare practitioner acting within the scope of his or her professional licensure to determine what information a reasonable person in the patient's condition and circumstances would consider material to a decision to accept or refuse a proposed treatment or procedure. Information that is commonly appreciated need not be disclosed. The disclosure of the material information and obtaining informed consent shall be the responsibility of the physician. The disclosure of the material information and obtaining informed consent shall be the responsibility of the licensed healthcare practitioner who, acting within the scope of his or her professional licensure, performs or orders the procedure or treatment for which informed consent is required.

(b) The information material to a decision concerning the administration of a psychotherapeutic drug or physical restraint, or the prolonged use of a device that may lead to the inability of the patient to regain use of a normal bodily function shall include at least the following:

- (1) The reason for the treatment and the nature and seriousness of the patient's illness.
- (2) The nature of the procedures to be used in the proposed treatment including their probable frequency and duration.
- (3) The probable degree and duration (temporary or permanent) of improvement or remission, expected with or without such treatment.
- (4) The nature, degree, duration and probability of the side effects and significant risks, commonly known by the health professions.
- (5) The reasonable alternative treatments and risks, and why the health professional is recommending this particular treatment.
- (6) That the patient has the right to accept or refuse the proposed treatment, and if he or she consents, has the right to revoke his or her consent for any reason at any time.

Mental Health Medications: Antipsychotics

Adapted from Mental Health Medications – National Institute of Mental Health U.S. Department of Health and Human Services

To see more go to:

www.nih.gov

- Click on "Health Topics"
- Click on "Publications"
- Select "Mental Health Medications"

Mental Health Medications: Antipsychotics Benefits and Risks



Company Phone number
Company FAX number
Website Address
Company Address

Mental Health Medications: Antipsychotics

Antipsychotic medications are used to treat schizophrenia and schizophrenia-related disorders, psychotic symptoms, hallucinations and delusions (breaks in reality). Some of the “typical” antipsychotics include:

- Chlorpromazine (Thorazine)
- Haloperidol (Haldol)
- Perphenazine
- Fluphenazine

In 2009 new antipsychotic medications were developed. These new medications are called second generation or “atypical” antipsychotics. Some of the “atypical” antipsychotics include:


- Risperidone (Risperdal)
- Olanzapine (Zyprexa)
- Quetiapine (Seroquel)
- Ziprasidone (Geodon)
- Aripiprazole (Abilify)
- Paliperidone (Invega)

NOTE: The FDA issued a Public Health Advisory for atypical antipsychotic medications. The FDA determined that the death rates are higher for elderly people with dementia when taking this medication. A review of the data has found a risk with conventional antipsychotics as well. Antipsychotic medications are not FDA approved for the treatment of behavioral disorders in patients with dementia.

What are the Side Effects?

Side effects may include, but not be limited to:

- Drowsiness
- Dizziness when changing positions
- Blurred vision
- Rapid heartbeat
- Sensitivity to the sun
- Skin rashes
- Major weight gain
- Changes in metabolism
- Rigidity
- Persistent muscle spasms
- Tremors restlessness



Long term use of typical antipsychotic medications may lead to a condition called tardive dyskinesia (TD). TD causes muscle movements a person cannot control the movements commonly happen around the mouth. TD can range from mild to severe, and in some people the problem cannot be cured. Sometimes people with TD recover partially or fully after they stop taking the medication.

Every year, an estimated 5 percent of people taking typical antipsychotics get TD. The condition happens to fewer people who take the new, atypical antipsychotics, but some people may still get TD.

How are Antipsychotics Taken and How do People Respond to Them?

Antipsychotics are usually pills that people swallow or liquid they can drink. Some antipsychotics are shots that are given once or twice a month.

Symptoms of schizophrenia, such as feeling agitated and having hallucinations, usually go away within days. Symptoms like delusions usually go away within a few weeks. After about six weeks, many people will see a lot of improvement.

Add Facility Information Here